AMOXICILLIN AND CLAVULANATE POTASSIUM

Post-LOE

Novartis

ANDAORALFOR SUSPENSION

Approved

Dec 2002

Lifecycle

Post-LOE

Competitive Pressure

30/100

Data completeness

3/8 — Basic

AMOXICILLIN AND CLAVULANATE POTASSIUM by Novartis is extended-release tablets is an antibacterial drug [see microbiology ( )]. Approved for infections in adults, equal to 40 kg, acute bacterial sinusitis due to confirmed and 2 more indications. First approved in 2002.

Drug data last refreshed 23h ago

Mechanism of Action

extended-release tablets is an antibacterial drug [see Microbiology ( )].

Indications (5)

infections in adults equal to 40 kg acute bacterial sinusitis due to confirmed

Worked on AMOXICILLIN AND CLAVULANATE POTASSIUM at Novartis? Share your interview experience or compensation data (+7 days Pro)

Data Sources

Drug label: DailyMed / FDA
Clinical trials: ClinicalTrials.gov
Patent data: FDA Orange Book
Spending data: CMS Medicare

The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.